Free Trial

B. Riley Issues Pessimistic Estimate for biote Earnings

biote logo with Medical background

biote Corp. (NASDAQ:BTMD - Free Report) - Investment analysts at B. Riley lowered their FY2025 EPS estimates for biote in a research note issued on Thursday, August 7th. B. Riley analyst J. Van. Sinderen now expects that the company will post earnings of $0.25 per share for the year, down from their previous forecast of $0.31. B. Riley currently has a "Neutral" rating and a $4.00 target price on the stock. The consensus estimate for biote's current full-year earnings is $0.75 per share. B. Riley also issued estimates for biote's Q4 2025 earnings at $0.02 EPS, FY2026 earnings at $0.29 EPS and FY2027 earnings at $0.42 EPS.

biote (NASDAQ:BTMD - Get Free Report) last announced its earnings results on Wednesday, August 6th. The company reported $0.10 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.06 by $0.04. The company had revenue of $48.86 million during the quarter, compared to analyst estimates of $49.52 million. biote had a net margin of 15.73% and a negative return on equity of 21.00%.

Separately, Wall Street Zen lowered shares of biote from a "strong-buy" rating to a "hold" rating in a research report on Saturday, August 9th.

Read Our Latest Analysis on biote

biote Trading Up 0.8%

NASDAQ BTMD traded up $0.02 during trading hours on Monday, hitting $3.00. 144,212 shares of the company's stock traded hands, compared to its average volume of 171,274. The business's fifty day moving average price is $3.95 and its two-hundred day moving average price is $3.96. The firm has a market capitalization of $164.35 million, a P/E ratio of 3.30 and a beta of 1.21. biote has a 52 week low of $2.76 and a 52 week high of $6.98.

Institutional Trading of biote

Large investors have recently added to or reduced their stakes in the business. Acadian Asset Management LLC boosted its position in shares of biote by 15.0% in the first quarter. Acadian Asset Management LLC now owns 700,871 shares of the company's stock worth $2,330,000 after purchasing an additional 91,672 shares during the period. Dimensional Fund Advisors LP boosted its position in shares of biote by 0.5% in the fourth quarter. Dimensional Fund Advisors LP now owns 681,524 shares of the company's stock worth $4,211,000 after purchasing an additional 3,065 shares during the period. Geode Capital Management LLC boosted its position in shares of biote by 7.2% in the second quarter. Geode Capital Management LLC now owns 616,697 shares of the company's stock worth $2,480,000 after purchasing an additional 41,333 shares during the period. Hillsdale Investment Management Inc. boosted its position in shares of biote by 24.2% in the second quarter. Hillsdale Investment Management Inc. now owns 420,273 shares of the company's stock worth $1,689,000 after purchasing an additional 81,829 shares during the period. Finally, Northern Trust Corp boosted its position in shares of biote by 9.9% in the fourth quarter. Northern Trust Corp now owns 288,336 shares of the company's stock worth $1,782,000 after purchasing an additional 25,873 shares during the period. 21.68% of the stock is currently owned by institutional investors.

biote Company Profile

(Get Free Report)

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support.

Featured Articles

Earnings History and Estimates for biote (NASDAQ:BTMD)

Should You Invest $1,000 in biote Right Now?

Before you consider biote, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and biote wasn't on the list.

While biote currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Stocks With Explosive Upside
September Slowdown: 3 Stocks to Buy When the Pullback Comes
3 Overlooked Stocks Riding the AI Data Center Boom

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines